Literature DB >> 26118307

Predicting clinical severity based on substitutions near epitope A of influenza A/H3N2.

Hong Kai Lee1, Julian Wei-Tze Tang2, Tze Ping Loh3, Lynette Lin-Ean Oon4, Evelyn Siew-Chuan Koay5.   

Abstract

Epitopes are the main targets for specific antibodies in the host defense systems. Recent studies have shown that amino acid (aa) substitutions located within the influenza A/H3N2 hemagglutinin 1 (HA1) epitopes A-E, particularly in A and B, result in antigenic drift. Viruses with such drift mutations may have resulted in more severe influenza-related illness during influenza epidemics between late 2012 and early 2015. We sought to quantify vaccine mismatches in epitopes A-E of the HA1 protein, and correlate these with the severity of the patient's illness. The influenza A/H3N2 clinical samples were collected between April 2009 and November 2013 (n=206). Patients were clinically stratified into groups with mild, moderate, and severe influenza-like illness (ILI). The impact of the number of aa mismatches in each of epitopes A-E, gender, age groups (⩽18, 19-64, ⩾65 years), and comorbidities on the likelihood that patients would suffer moderate and/or severe ILI due to influenza A/H3N2 infection were assessed. A higher number of aa mismatches in epitope A between the vaccine and locally circulating viruses correlated with more severe influenza infection, although this correlation was most significant with pre-existing comorbidities. A practical application of this finding would be to monitor patients (especially those in high-risk groups) infected with such viruses more closely, as they are at increased risk of developing more serious disease. Epidemiologically, it was of interest to note that viruses from subclade 3A of Victoria/208 strain were not detected in Singapore between 2009 and 2012. By contrast, these viruses were detected at a prevalence of up to 40% in the 2011-2012 influenza seasons in other regions of the Northern and Southern hemispheres. Such findings support the rationale for more regionally customized seasonal influenza vaccine compositions to optimize the protection of the population against locally circulating virus strains.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Antigenic; Epitope; H3N2; Influenza; Severe; Vaccine

Mesh:

Substances:

Year:  2015        PMID: 26118307     DOI: 10.1016/j.meegid.2015.06.025

Source DB:  PubMed          Journal:  Infect Genet Evol        ISSN: 1567-1348            Impact factor:   3.342


  4 in total

1.  Descriptive study of severe hospitalized cases of laboratory-confirmed influenza during five epidemic seasons (2010-2015).

Authors:  Núria Torner; Ana Martínez; Luca Basile; MMar Mosquera; Andrés Antón; Cristina Rius; M Rosa Sala; Sofia Minguell; Elsa Plasencia; Mónica Carol; Pere Godoy; Núria Follia; Irene Barrabeig; M Angeles Marcos; Tomàs Pumarola; Mireia Jané
Journal:  BMC Res Notes       Date:  2018-04-14

2.  RNA Sequencing of H3N2 Influenza Virus-Infected Human Nasal Epithelial Cells from Multiple Subjects Reveals Molecular Pathways Associated with Tissue Injury and Complications.

Authors:  Kai Sen Tan; Anand Kumar Andiappan; Bernett Lee; Yan Yan; Jing Liu; See Aik Tang; Josephine Lum; Ting Ting He; Yew Kwang Ong; Mark Thong; Hui Fang Lim; Hyung Won Choi; Olaf Rotzschke; Vincent T Chow; De Yun Wang
Journal:  Cells       Date:  2019-08-27       Impact factor: 6.600

3.  Genome-Wide Analysis of Evolutionary Markers of Human Influenza A(H1N1)pdm09 and A(H3N2) Viruses May Guide Selection of Vaccine Strain Candidates.

Authors:  Sergei S Belanov; Dmitrii Bychkov; Christian Benner; Samuli Ripatti; Teija Ojala; Matti Kankainen; Hong Kai Lee; Julian Wei-Tze Tang; Denis E Kainov
Journal:  Genome Biol Evol       Date:  2015-11-27       Impact factor: 3.416

4.  Genetic divergence of Influenza A(H3N2) amino acid substitutions mark the beginning of the 2016-2017 winter season in Israel.

Authors:  Aharona Glatman-Freedman; Yaron Drori; Sharon Alexandra Beni; Nehemya Friedman; Rakefet Pando; Hanna Sefty; Ilana Tal; John McCauley; Galia Rahav; Nathan Keller; Tamy Shohat; Ella Mendelson; Musa Hindiyeh; Michal Mandelboim
Journal:  J Clin Virol       Date:  2017-06-04       Impact factor: 3.168

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.